Drug recall · March 14, 2018
Lynparza recall
Why: Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Lynparza (olaparib) capsules 50 mg, 112 count bottles, Rx only, Manufactured for: Astra Zeneca Pharmaceuticals LP Wilmington, DE 19850 by: Patheon Pharmaceuticals, Inc. Cincinnati OH 45237 Product of Switzerland NDC 0310-0657-58
- Lots / codes
HN0406 02/2018 JH0341 03/2018 JH0342 03/2018 JH0147 03/2018 JC0391 04/2018 JK0147 04/2018 JL0184 04/2018 JC0402 05/2018
- Quantity
- 18056 bottles
- Company
- AstraZeneca Pharmaceuticals LP, Wilmington, DE
- Distribution
- Nationwide
- Initiated
- February 23, 2018 · Voluntary: Firm initiated
- Classified
- March 9, 2018
- Reported
- March 14, 2018
- Ended
- February 26, 2019
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.